CLINICAL TRIALS PROFILE FOR REPATHA

All Clinical Trials for REPATHA

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01375764 ↗	Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects	Completed	Amgen	Phase 2	2011-07-28	The primary objective was to evaluate the effect of 12 weeks of subcutaneous evolocumab (AMG 145), compared with ezetimibe, on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in patients with hypercholesterolemia unable to tolerate an effective dose of a statin.
NCT01375777 ↗	Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels	Completed	Amgen	Phase 2	2011-07-06	The primary objective was to evaluate the effect of 12 weeks of subcutaneous evolocumab (AMG 145) every 2 weeks (Q2W) or every 4 weeks (Q4W), compared with placebo, on the percent change from baseline in LDL-C when used as monotherapy in adults with hypercholesterolemia.
NCT01516879 ↗	Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study	Completed	Amgen	Phase 3	2012-01-05	To evaluate the efficacy, safety, and tolerability of 52 weeks of subcutaneous (SC) evolocumab (AMG 145) compared with placebo when added to assigned background lipid-lowering therapy.
NCT01588496 ↗	Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities	Completed	Amgen	Phase 2/Phase 3	2012-04-05	A study to determine the safety, tolerability, and efficacy of evolocumab (AMG 145) in patients with homozygous familial hypercholesterolemia (HoFH).
NCT01763827 ↗	Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2	Completed	Amgen	Phase 3	2013-01-21	The primary objective was to evaluate the effect of 12 weeks of evolocumab subcutaneous (SC) monotherapy every 2 weeks (Q2W) and monthly (QM), compared with placebo and ezetimibe, on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in adults with a 10-year Framingham risk score of 10% or less.
NCT01763866 ↗	LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2	Completed	Amgen	Phase 3	2013-01-15	The primary objective was to evaluate the effect of 12 weeks of evolocumab administered subcutaneously every 2 weeks (Q2W) and monthly (QM) when used in combination with a statin, compared with placebo, on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in patients with primary hypercholesterolemia and mixed dyslipidemia.

Clinical Trial Conditions for REPATHA

Condition Name

Condition Name for REPATHA
Intervention	Trials
Hyperlipidemia	7
Coronary Artery Disease	5
Hypercholesterolemia	3
Familial Hypercholesterolemia	2

Condition MeSH

Condition MeSH for REPATHA
Intervention	Trials
Hyperlipidemias	15
Hypercholesterolemia	12
Dyslipidemias	10
Atherosclerosis	8

Clinical Trial Locations for REPATHA

Trials by Country

Trials by Country for REPATHA
Location	Trials
United States	357
Japan	92
Canada	78
Australia	53
Spain	49

Trials by US State

Trials by US State for REPATHA
Location	Trials
New York	20
Ohio	17
California	17
Florida	14
North Carolina	13

Clinical Trial Progress for REPATHA

Clinical Trial Phase

Clinical Trial Phase for REPATHA
Clinical Trial Phase	Trials
Phase 4	23
Phase 3	18
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for REPATHA
Clinical Trial Phase	Trials
Completed	23
Recruiting	21
Not yet recruiting	5

Clinical Trial Sponsors for REPATHA

Sponsor Name

Sponsor Name for REPATHA
Sponsor	Trials
Amgen	34
NYU Langone Health	3
University of California, Los Angeles	2

Sponsor Type

Sponsor Type for REPATHA
Sponsor	Trials
Other	54
Industry	40
NIH	1